KRAS and familial pancreatic carcinoma: In addition, it was observed that patients with PD (P = 0.034) or some types of tumor (e.g., esophageal cancer, colorectal cancer, and pancreatic cancer) (P < 0.01) (Tables 1 and 2) and patients with colorectal cancer who had KRAS mutations (P = 0.039) (Table 3) were more likely to have HDP after subsequent immunotherapy.